1414 ET - Life sciences and diagnostic tools companies are primed for surprisingly good 1Qs amid positive pre-announcements from Pacific Biosciences of California, Qiagen NV and Bruker, but don't fall for the initial positive news, Bank of America analysts say in a research note. "We wouldn't overreact to these initial prints," the analysts say, adding headwinds from National Institutes of Health budget cuts, tariffs and a trade war with China only materialized recently, giving companies one to two months of regular business activity in the 1Q. The real risk, then, lies in 2Q/3Q and the rest of FY25, the analysts say. They expect softer commentary particularly from academic and government exposed companies like Illumina, 10x Genomics and others, while diagnostics companies are likely a safer bet, they say. (kelly.cloonan@wsj.com)
(END) Dow Jones Newswires
April 14, 2025 14:14 ET (18:14 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。